{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:29:14Z","timestamp":1785461354121,"version":"3.56.0"},"reference-count":43,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Age-related macular degeneration (AMD) is a retinal disease prevalent in the elderly population, with two main subtypes: dry (non-exudative) and neovascular (wet or exudative). Neovascular AMD (nAMD) has a more debilitating prognosis than dry AMD, making it the third leading cause of blindness. Intravitreal injections of anti-vascular endothelial growth factor (IV anti-VEGF) are the most effective and widely accepted treatment for nAMD. However, a significant number of nAMD patients exhibit suboptimal responses to IV anti-VEGF therapy, with the underlying mechanisms not yet fully understood. We hypothesized that genetic polymorphisms associated with blood hypercoagulation may also contribute to suboptimal responses to IV anti-VEGF therapy.<\/jats:p>\n<jats:p>This study recruited 20 nAMD patients, who were divided into two groups based on their treatment responses after four years: 10 patients with suboptimal responses to IV anti-VEGF therapy and 10 patients with optimal responses. After obtaining institutional ethics board approval, we retrospectively evaluated relevant clinical records of twenty patients diagnosed with nAMD. Patient clinical data were accessed between 20th March 2021 -1st April 2021 for research purposes only. We genotyped peripheral blood DNA from each patient for hypercoagulation-related polymorphisms, including Factor V Leiden (rs6025), prothrombin c.20210G&gt;A (rs1799963), MTHFR A1298C (rs1801131), MTHFR C677T (rs1801133), and SERPINE 1 (PAI-1-675 4G\/5G) (rs1799768), and statistically compared the frequencies.<\/jats:p>\n<jats:p>Heterozygous and homozygous mutations in the <jats:italic>SERPINE1<\/jats:italic> gene specifically PAI-1 promoter region PAI-1-675 4G\/5G (rs1799768) were identified as risk factors for resistance to IV anti-VEGF therapy in nAMD patients (\u03c7\u00b2 test, p = 0.006). No other polymorphisms of the above-mentioned genes were statistically significant (p &gt; 0.05).<\/jats:p>\n<jats:p>The failure of IV anti-VEGF therapy in nAMD patients may be influenced by various factors, one of which may be the inherited PAI-1-675 4G\/5G (rs1799768) polymorphisms which normally known to contribute hypercoagulation. Further research involving a larger cohort is necessary to uncover the interplay between hereditary factors and other elements contributing to the inefficacy of IV anti-VEGF therapy in nAMD.<\/jats:p>","DOI":"10.1371\/journal.pone.0317511","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T18:26:52Z","timestamp":1741285612000},"page":"e0317511","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Indications of the SERPINE 1 variant rs1799768\u2019s role in anti-VEGF therapy resistance in neovascular age-related macular degeneration"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3131-0795","authenticated-orcid":true,"given":"Muhammer \u00d6zg\u00fcr","family":"\u00c7EV\u0130K","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z\u00fchal","family":"Mert Altunta\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sad\u0131k G\u00f6rkem","family":"\u00c7evik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"issue":"1","key":"pone.0317511.ref001","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41572-021-00265-2","article-title":"Age-related macular degeneration","volume":"7","author":"M Fleckenstein","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"pone.0317511.ref002","doi-asserted-by":"crossref","first-page":"e0278925","DOI":"10.1371\/journal.pone.0278925","article-title":"Spatial characterization of the effect of age and sex on macular layer thicknesses and foveal pit morphology","volume":"17","author":"D Romero-Bascones","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"pone.0317511.ref003","doi-asserted-by":"crossref","first-page":"e0261897","DOI":"10.1371\/journal.pone.0261897","article-title":"Blindness and visual impairment in Central Europe","volume":"17","author":"M Glatz","year":"2022","journal-title":"PLoS One"},{"issue":"29\u201330","key":"pone.0317511.ref004","first-page":"513","article-title":"The Diagnosis and Treatment of Age-Related Macular Degeneration","volume":"117","author":"A Stahl","year":"2020","journal-title":"Dtsch Arztebl Int"},{"issue":"6","key":"pone.0317511.ref005","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1159\/000517520","article-title":"Age-Related Macular Degeneration: Pathophysiology, Management, and Future Perspectives","volume":"244","author":"R Flores","year":"2021","journal-title":"Ophthalmologica"},{"issue":"2","key":"pone.0317511.ref006","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7861\/clinmed.2022-0057","article-title":"Clinical approach to vision loss: a review for general physicians","volume":"22","author":"A Raharja","year":"2022","journal-title":"Clin Med (Lond)"},{"key":"pone.0317511.ref007","doi-asserted-by":"crossref","first-page":"1141077","DOI":"10.3389\/fphar.2023.1141077","article-title":"Anti-vascular endothelial growth factor monotherapy or combined with verteporfin photodynamic therapy for retinal angiomatous proliferation: a systematic review with meta-analysis","volume":"14","author":"M Fallico","year":"2023","journal-title":"Front Pharmacol"},{"key":"pone.0317511.ref008","doi-asserted-by":"crossref","first-page":"917","DOI":"10.2147\/OPTH.S231913","article-title":"Neovascular Age-Related Macular Degeneration (nAMD): A Review of Emerging Treatment Options","volume":"16","author":"CS Tan","year":"2022","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"pone.0317511.ref009","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/s41433-022-02097-0","article-title":"Developing and validating a multivariable prediction model which predicts progression of intermediate to late age-related macular degeneration-the PINNACLE trial protocol","volume":"37","author":"J Sutton","year":"2023","journal-title":"Eye (Lond)"},{"issue":"5\u20136","key":"pone.0317511.ref010","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0268-9499(97)80107-5","article-title":"Identification of an 18 basepair deletion in the PAI-1 gene promoter region in a family with thrombotic disease","volume":"11","author":"G Falk","year":"1997","journal-title":"Fibrinolysis and Proteolysis"},{"issue":"6","key":"pone.0317511.ref011","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1073\/pnas.92.6.1851","article-title":"Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction","volume":"92","author":"P Eriksson","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pone.0317511.ref012","doi-asserted-by":"crossref","first-page":"7375","DOI":"10.1038\/s41598-018-25810-0","article-title":"Evaluation of pre-analytical factors affecting plasma DNA analysis","volume":"8","author":"H Markus","year":"2018","journal-title":"Sci Rep"},{"key":"pone.0317511.ref013","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13072-015-0050-4","article-title":"Making sense of GWAS: using epigenomics and genome engineering to understand the functional relevance of SNPs in non-coding regions of the human genome","volume":"8","author":"YG Tak","year":"2015","journal-title":"Epigenetics Chromatin"},{"issue":"1","key":"pone.0317511.ref014","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/s12886-022-02550-4","article-title":"Relationship between serum and tear levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in diabetic retinopathy","volume":"22","author":"NB Jasmiad","year":"2022","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"pone.0317511.ref015","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2217\/14622416.10.1.81","article-title":"Predictive role of C677T MTHFR polymorphism in variable efficacy of photodynamic therapy for neovascular age-related macular degeneration","volume":"10","author":"F Parmeggiani","year":"2009","journal-title":"Pharmacogenomics"},{"issue":"3","key":"pone.0317511.ref016","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.ophtha.2009.08.028","article-title":"Impact of coagulation-balance gene predictors on efficacy of photodynamic therapy for choroidal neovascularization in pathologic myopia","volume":"117","author":"F Parmeggiani","year":"2010","journal-title":"Ophthalmology"},{"issue":"7","key":"pone.0317511.ref017","first-page":"976","article-title":"Association between VEGF-A and VEGFR-2 polymorphisms and response to treatment of neovascular AMD with anti-VEGF agents: a meta-analysis","volume":"101","author":"M Wu","year":"2017","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"pone.0317511.ref018","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1159\/000524942","article-title":"Pathophysiology of Age-Related Macular Degeneration: Implications for Treatment","volume":"65","author":"J Garcia-Garcia","year":"2022","journal-title":"Ophthalmic Res"},{"issue":"33","key":"pone.0317511.ref019","doi-asserted-by":"crossref","first-page":"15813","DOI":"10.1016\/S0021-9258(18)47659-4","article-title":"Immunological identity of heparin-dependent plasma and urinary protein C inhibitor and plasminogen activator inhibitor-3","volume":"262","author":"MJ Heeb","year":"1987","journal-title":"J Biol Chem"},{"issue":"6","key":"pone.0317511.ref020","doi-asserted-by":"crossref","first-page":"e100148","DOI":"10.1371\/journal.pone.0100148","article-title":"Differential methylation of genes associated with cell adhesion in preeclamptic placentas","volume":"9","author":"L Anton","year":"2014","journal-title":"PLoS One"},{"key":"pone.0317511.ref021","first-page":"2024.09.16.612699","article-title":"High-throughput amino acid-level characterization of the interactions of plasminogen activator inhibitor-1 with variably divergent proteases","author":"LM Haynes","year":"2024","journal-title":"bioRxiv"},{"key":"pone.0317511.ref022","doi-asserted-by":"crossref","first-page":"859979","DOI":"10.3389\/fcvm.2022.859979","article-title":"Systematic Review and Meta-Analysis of SERPINE1 4G\/5G Insertion\/Deletion Variant With Circulating Lipid Levels","volume":"9","author":"Z Luo","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"pone.0317511.ref023","doi-asserted-by":"crossref","first-page":"622473","DOI":"10.3389\/fcvm.2020.622473","article-title":"Targeting PAI-1 in Cardiovascular Disease: Structural Insights Into PAI-1 Functionality and Inhibition","volume":"7","author":"M Sillen","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"pone.0317511.ref024","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.biochi.2024.09.010","article-title":"Orchestra of ligand-activated transcription factors in the molecular symphony of SERPINE 1 \/ PAI-1 gene regulation","volume":"228","author":"A Vrzalova","year":"2025","journal-title":"Biochimie"},{"issue":"16","key":"pone.0317511.ref025","first-page":"1959","article-title":"PAI-1 genetic polymorphisms influence septic patients\u2019 outcomes by regulating neutrophil activity","volume":"136","author":"S Jiang","year":"2023","journal-title":"Chin Med J (Engl)"},{"issue":"2","key":"pone.0317511.ref026","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1023\/A:1008907001042","article-title":"Clinical implications of elevated PAI-1 revisited: multiple arterial thrombosis in a patient with essential thrombocythemia and elevated plasminogen activator inhibitor-1 (PAI-1) levels: a case report and review of the literature","volume":"8","author":"SL Senno","year":"1999","journal-title":"J Thromb Thrombolysis"},{"issue":"10","key":"pone.0317511.ref027","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1161\/01.ATV.0000242905.41404.68","article-title":"PAI-1 and the metabolic syndrome: links, causes, and consequences","volume":"26","author":"M-C Alessi","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"pone.0317511.ref028","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.2741\/2285","article-title":"Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis","volume":"12","author":"Y Aso","year":"2007","journal-title":"Front Biosci"},{"issue":"41","key":"pone.0317511.ref029","doi-asserted-by":"crossref","first-page":"6986","DOI":"10.1038\/sj.onc.1207859","article-title":"Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth","volume":"23","author":"K Bajou","year":"2004","journal-title":"Oncogene"},{"issue":"2","key":"pone.0317511.ref030","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1172\/JCI114211","article-title":"Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA\/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA","volume":"84","author":"OF Wagner","year":"1989","journal-title":"J Clin Invest"},{"issue":"4","key":"pone.0317511.ref031","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.thromres.2012.06.023","article-title":"The Biochemistry, Physiology and Pathological roles of PAI-1 and the requirements for PAI-1 inhibition in vivo","volume":"130","author":"B Van De Craen","year":"2012","journal-title":"Thromb Res"},{"issue":"10","key":"pone.0317511.ref032","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.1167\/iovs.09-3619","article-title":"Plasminogen activator inhibitor-1 (PAI-1) facilitates retinal angiogenesis in a model of oxygen-induced retinopathy","volume":"50","author":"A Basu","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"pone.0317511.ref033","first-page":"1561","article-title":"Plasminogen Activators and Inhibitors in the Corneas of Mice Infected with Pseudomonas aeruginosa","volume":"42","author":"RS Berk","year":"2001","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"pone.0317511.ref034","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/archopht.123.2.220","article-title":"Plasminogen activator inhibitor-1 in the aqueous humor of patients with and without glaucoma","volume":"123","author":"J Dan","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"pone.0317511.ref035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.exer.2004.06.006","article-title":"Plasminogen activator inhibitor-1 (PAI-1) stimulates human corneal epithelial cell adhesion and migration in vitro","volume":"80","author":"Z Wang","year":"2005","journal-title":"Exp Eye Res"},{"issue":"9","key":"pone.0317511.ref036","doi-asserted-by":"crossref","first-page":"eabm1896","DOI":"10.1126\/sciadv.abm1896","article-title":"PAI-1 is a vascular cell-specific HIF-2-dependent angiogenic factor that promotes retinal neovascularization in diabetic patients","volume":"8","author":"Y Qin","year":"2022","journal-title":"Sci Adv"},{"issue":"8","key":"pone.0317511.ref037","first-page":"2296","article-title":"Plasminogen activator inhibitor (PAI)-1 overexpression in retinal microvessels of PAI-1 transgenic mice","volume":"41","author":"MB Grant","year":"2000","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"pone.0317511.ref038","doi-asserted-by":"crossref","first-page":"253","DOI":"10.21608\/besps.2008.36961","article-title":"Evaluation of Homocysteine and Plasminogen Activator Inhibitor-1 Changes in Age Related Macular Degeneration","volume":"28","author":"A Mahmoud","year":"2008","journal-title":"BESPS"},{"key":"pone.0317511.ref039","doi-asserted-by":"crossref","first-page":"692272","DOI":"10.3389\/fmed.2021.692272","article-title":"Novel Possible Protein Targets in Neovascular Age-Related Macular Degeneration: A Pilot Study Experiment","volume":"8","author":"BNL Coronado","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"pone.0317511.ref040","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1158\/1541-7786.MCR-23-0015","article-title":"Continuous Administration of Anti-VEGFA Antibody Upregulates PAI-1 Secretion from Ovarian Cancer Cells via miR-143-3p Downregulation","volume":"21","author":"T Yagi","year":"2023","journal-title":"Mol Cancer Res"},{"key":"pone.0317511.ref041","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-1-60761-938-3_5","article-title":"The blood-retinal barrier: structure and functional significance","volume":"686","author":"EA Runkle","year":"2011","journal-title":"Methods Mol Biol"},{"issue":"1","key":"pone.0317511.ref042","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12974-024-03190-9","article-title":"Suppression of inner blood-retinal barrier breakdown and pathogenic M\u00fcller glia activation in ischemia retinopathy by myeloid cell depletion","volume":"21","author":"L Zhou","year":"2024","journal-title":"J Neuroinflammation"},{"key":"pone.0317511.ref043","volume-title":"KEGG pathway: map04933","author":"Kyoto Encyclopedia of Genes and Genomes"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0317511","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T18:27:10Z","timestamp":1741285630000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0317511"}},"subtitle":[],"editor":[{"given":"Jeffrey S","family":"Isenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0317511","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]}}}